[go: up one dir, main page]

WO1997009348A3 - Recepteur orphelin - Google Patents

Recepteur orphelin Download PDF

Info

Publication number
WO1997009348A3
WO1997009348A3 PCT/EP1996/003933 EP9603933W WO9709348A3 WO 1997009348 A3 WO1997009348 A3 WO 1997009348A3 EP 9603933 W EP9603933 W EP 9603933W WO 9709348 A3 WO9709348 A3 WO 9709348A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
PCT/EP1996/003933
Other languages
English (en)
Other versions
WO1997009348A2 (fr
Inventor
Jan-Ake Gustafsson
George G J M Kuiper
Eva Enmark
Original Assignee
Jan-Ake Gustafsson
George G J M Kuiper
Eva Enmark
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1997009348(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Priority to US08/836,620 priority Critical patent/US5958710A/en
Application filed by Jan-Ake Gustafsson, George G J M Kuiper, Eva Enmark, Karobio Ab filed Critical Jan-Ake Gustafsson
Priority to EP96931047A priority patent/EP0792292B2/fr
Priority to KR1019970703038A priority patent/KR100263137B1/ko
Priority to CA002201098A priority patent/CA2201098C/fr
Priority to JP09510877A priority patent/JP3131649B2/ja
Priority to DK96931047T priority patent/DK0792292T4/da
Priority to DE69603827T priority patent/DE69603827T3/de
Priority to DE0792292T priority patent/DE792292T1/de
Priority to AU69880/96A priority patent/AU715528B2/en
Publication of WO1997009348A2 publication Critical patent/WO1997009348A2/fr
Publication of WO1997009348A3 publication Critical patent/WO1997009348A3/fr
Priority to GR980300029T priority patent/GR980300029T1/el
Priority to GR990402716T priority patent/GR3031618T3/el
Priority to US10/278,481 priority patent/US7132261B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau récepteur nucléaire s'apparentant au récepteur d'oestrogène, désigné ici par 'ERβ', lequel possède la séquence d'acides aminés des figures 1, 13A ou 14A ou sensiblement la même séquence d'acides aminés que celle représentée sur les figures 1, 13A ou 13B, ou bien une séquence d'acides aminés similaire fonctionnellement à cette dernière séquence. L'invention concerne également des séquences d'ADN codant ce récepteur, lequel peut être utile pour isoler des molécules dans le traitement de troubles tels que le cancer de la prostate, l'adénome prostatique, l'ostéoporose ou les troubles cardio-vasculaires, ainsi que dans l'essai de substances à la recherche d'effets oestrogéniques ou d'autres effets hormonaux
PCT/EP1996/003933 1995-09-08 1996-09-09 Recepteur orphelin WO1997009348A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP09510877A JP3131649B2 (ja) 1995-09-08 1996-09-09 オーファン レセプター
DK96931047T DK0792292T4 (da) 1995-09-08 1996-09-09 Orphan-receptor
DE69603827T DE69603827T3 (de) 1995-09-08 1996-09-09 Östrogen-Rezeptor
DE0792292T DE792292T1 (de) 1995-09-08 1996-09-09 Waisen-rezeptor
US08/836,620 US5958710A (en) 1995-09-08 1996-09-09 Orphan receptor
AU69880/96A AU715528B2 (en) 1995-09-08 1996-09-09 Orphan receptor
EP96931047A EP0792292B2 (fr) 1995-09-08 1996-09-09 Recepteur de l'oestrogène
KR1019970703038A KR100263137B1 (ko) 1995-09-08 1996-09-09 오판 수용체
CA002201098A CA2201098C (fr) 1995-09-08 1996-09-09 Recepteur orphelin
GR980300029T GR980300029T1 (en) 1995-09-08 1998-04-30 Orphan receptor
GR990402716T GR3031618T3 (en) 1995-09-08 1999-10-26 Orphan receptor
US10/278,481 US7132261B2 (en) 1995-09-08 2002-10-23 Orphan receptor

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GB9607532.0 1996-05-08
GB9518272.1 1996-05-08
GB9605550.4 1996-05-08
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
GB9609576.5 1996-05-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08836620 A-371-Of-International 1996-09-09
US33305799A Continuation 1995-09-08 1999-06-14

Publications (2)

Publication Number Publication Date
WO1997009348A2 WO1997009348A2 (fr) 1997-03-13
WO1997009348A3 true WO1997009348A3 (fr) 1997-04-24

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003933 WO1997009348A2 (fr) 1995-09-08 1996-09-09 Recepteur orphelin

Country Status (12)

Country Link
US (2) US5958710A (fr)
EP (2) EP0792292B2 (fr)
JP (4) JP3131649B2 (fr)
KR (1) KR100263137B1 (fr)
AT (1) ATE183516T1 (fr)
AU (1) AU715528B2 (fr)
CA (1) CA2201098C (fr)
DE (2) DE69603827T3 (fr)
DK (1) DK0792292T4 (fr)
ES (1) ES2135249T5 (fr)
GR (2) GR980300029T1 (fr)
WO (1) WO1997009348A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060490B1 (en) 1996-03-26 2006-06-13 Akzo Nobel N.V. DNA encoding novel estrogen receptor

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866127A3 (fr) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, un homologue de récepteur d'hormone stéroide
WO1998056812A2 (fr) * 1997-06-10 1998-12-17 Karo Bio Ab Ligands se liant aux recepteurs d'oestrogenes
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (fr) * 1999-04-09 2005-03-02 Karo Bio Ab Récepteurs des oestrogènes et les maladies de l'os
WO2000061230A2 (fr) * 1999-04-09 2000-10-19 Karo Bio Ab Recepteur des oestrogenes et les os
WO2002064783A2 (fr) * 2001-02-09 2002-08-22 Lion Bioscience Ag Nouveaux cofacteurs du recepteur beta d'oestrogenes et procedes d'utilisation
WO2002070697A1 (fr) * 2001-03-02 2002-09-12 Lion Bioscience Ag Recepteur nucleaire l67 de mammifere et ses procedes d'utilisation
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
DE60220179T2 (de) 2001-11-19 2008-02-07 Eli Lilly And Co., Indianapolis Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (fr) * 2001-12-21 2003-06-21 Institut De Cardiologie Nouvelle therapie genique utilisant la strategie anti-sens pour les recepteurs estrogeniques (er .alpha. et/ou er .beta.) afin d'optimiser la regeneration vasculaire et la cardioprotection a la suite d'une lesion va sculaire
WO2004019953A1 (fr) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Procedes de traitement therapeutique
ES2427626T3 (es) 2003-02-21 2013-10-31 Styron Europe Gmbh Procedimiento para homo- o copolimerización de olefinas conjugadas
ES2338119T3 (es) 2003-04-21 2010-05-04 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor-beta de estrogeno.
SI1626974T1 (sl) 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
BRPI0413013A (pt) 2003-07-28 2006-10-03 Smithkline Beecham Corp composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
WO2005059563A2 (fr) * 2003-12-18 2005-06-30 Procognia Ltd. Procede d'analyse d'une glycomolecule
KR20070061536A (ko) 2004-09-07 2007-06-13 와이어쓰 ６Ｈ-[１]벤조피라노[４,３-ｂ]퀴놀린 및 에스트로겐제제로서의 이의 용도
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
AU655912B2 (en) * 1989-03-17 1995-01-19 Salk Institute For Biological Studies, The Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (fr) * 1993-11-10 1995-05-18 Arch Development Corporation Recepteur nucleaire ubiquiste: compositions et procedes
CA2200423C (fr) * 1996-03-26 2006-12-19 Sietse Mosselman Nouveaux recepteurs d'oestrogene

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ENMARK E. AND GUSTAFSSON J.: "Orphan nuclear receptors- the first eight years", MOLECULAR ENDOCRINOLOGY, vol. 10, no. 11, November 1996 (1996-11-01), pages 1293 - 1307, XP000645166 *
GREENE G L ET AL: "SEQUENCE AND EXPRESSION OF HUMAN ESTROGEN RECEPTOR COMPLEMENTARY DNA", SCIENCE, vol. 231, no. 4742, 7 March 1986 (1986-03-07), pages 1150 - 1154, XP000611679 *
KOIKE, S. ET AL.: "Molecular cloning and characterization of a rat estrogen receptor cDNA", NUCLEIC ACIDS RESEARCH, vol. 15, no. 6, 25 March 1987 (1987-03-25), pages 2499 - 2513, XP002026307 *
KUIPER G. ET AL.: "Cloning of a novel estrogen receptor expressed in rat prostate and ovary", PNAS U.S.A., vol. 93, no. 12, 11 June 1996 (1996-06-11), pages 5925 - 5930, XP002026309 *
LEES J. ET AL.: "Identification of two transactivation domains in the mouse oestrogen receptor", NUCLEIC ACIDS RESEARCH, vol. 17, no. 14, 25 July 1989 (1989-07-25), pages 5477 - 5488, XP002026308 *
MOSSELMAN, S. ET AL.: "ERbeta: identification and characterization of a novel human estrogen receptor", FEBS LETTERS, vol. 392, no. 1, 19 August 1996 (1996-08-19), pages 49 - 53, XP002026310 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060490B1 (en) 1996-03-26 2006-06-13 Akzo Nobel N.V. DNA encoding novel estrogen receptor

Also Published As

Publication number Publication date
JP2002010788A (ja) 2002-01-15
DK0792292T3 (da) 2000-02-07
EP0792292B2 (fr) 2009-04-15
ATE183516T1 (de) 1999-09-15
AU6988096A (en) 1997-03-27
GR980300029T1 (en) 1998-04-30
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
US7132261B2 (en) 2006-11-07
DK0792292T4 (da) 2009-07-20
KR100263137B1 (ko) 2000-08-01
DE69603827T3 (de) 2009-11-05
WO1997009348A2 (fr) 1997-03-13
ES2135249T5 (es) 2009-09-10
JP2005204666A (ja) 2005-08-04
DE69603827T2 (de) 2000-02-24
EP0935000A3 (fr) 1999-09-08
EP0792292B1 (fr) 1999-08-18
CA2201098C (fr) 2001-03-27
EP0935000A2 (fr) 1999-08-11
ES2135249T3 (es) 1999-10-16
US20030113803A1 (en) 2003-06-19
CA2201098A1 (fr) 1997-03-13
JPH11502417A (ja) 1999-03-02
AU715528B2 (en) 2000-02-03
GR3031618T3 (en) 2000-01-31
EP0792292A2 (fr) 1997-09-03
JP2005204667A (ja) 2005-08-04
JP3131649B2 (ja) 2001-02-05
US5958710A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
EP0935000A3 (fr) Récepteur orphelin
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
AU6045398A (en) Androgen synthesis inhibitors
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
CA2216601A1 (fr) Domaine intracellulaire de la proteine her-2/neu pour la prevention ou le traitement de tumeurs malignes
EP1310509A3 (fr) Nouveaux stéroides anti-oestrogènes, compositions pharmaceutiques associées et leur mode d'utilisation
PL328858A1 (en) Immunogenous peptides
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
WO1998018493A3 (fr) Conjugues utilises dans le traitement du cancer de la prostate
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
EP0920446A4 (fr) Analogues de la somatostatine cyclises par squelette a contrainte de conformation
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
WO1998027113A3 (fr) Melanocortines
WO1998058911A3 (fr) Agonistes de prostaglandines
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2000001813A3 (fr) Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene
ATE237334T1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO2005027833A3 (fr) Compose et methode de traitement du cancer de la prostate androgeno-independant
CA2288650A1 (fr) Procede de traitement de maladie mentale chez les mammiferes et composition a cet effet
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His
CA2340475A1 (fr) Recepteur orphelin
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
WO1999029719A3 (fr) Facteurs pancreatiques derives, et utilisations s'y rapportant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1996931047

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2201098

Country of ref document: CA

Ref country code: CA

Ref document number: 2201098

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970703038

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 08836620

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 510877

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996931047

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970703038

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996931047

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970703038

Country of ref document: KR